[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"choroidal-melanoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:choroidal-melanoma":83},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,63],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":13,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100516681",false,"NCT06007690","A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma","CoMpass","Inclusion Criteria:\n\n* Clinical diagnosis of primary indeterminate lesion or small choroidal melanoma (IL\u002FCM)\n* Have no evidence of metastatic disease confirmed by imaging\n* Be treatment naive for IL\u002FCM (subjects who received PDT may be eligible)\n\nExclusion Criteria:\n\n* Have known contraindications or sensitivities to the study drug or laser\n* Active ocular infection or disease","ALL","18 Years",{"count":18,"type":19},100,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).",[25,26,27,28],"Choroidal Melanoma","Indeterminate Lesions","Uveal Melanoma","Ocular Melanoma",[27,30,28,25],"Eye Cancer","RECRUITING","2026-02-26",{"date":34,"type":35},"2026-03-02","ACTUAL",{"date":37,"type":35},"2023-12-06",{"date":39,"type":19},"2028-08-15",{"name":41,"class":42},"Aura Biosciences","INDUSTRY",71,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":61,"locationsCount":62},"100625369","NCT07421739","Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) Subjects","Inclusion Criteria:\n\n* Have enrolled in the Aura-sponsored clinical trial AU-011-301.\n* Access to a connected device (i.e., smartphone, laptop, or tablet)\n\nExclusion Criteria:\n\n* None",{"count":50,"type":19},15,"OBSERVATIONAL","To assess subject-centric real-world evidence of QoL outcomes in subjects enrolled in the global Phase 3 AU-011-301 clinical trial.",[25,26,27,28],[27,30,28,25],"2026-02-17",{"date":57,"type":35},"2026-02-19",{"date":59,"type":35},"2025-11-12",{"date":39,"type":19},{"name":41,"class":42},1,{"id":64,"slug":4,"hasResults":10,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":13,"eligibilityCriteria":68,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":70,"conditions":71,"keywords":72,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":4},"100619003","NCT07338968","A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma","A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions\u002FSmall Choroidal Melanomas)","Inclusion Criteria:\n\n* Have received bel-sar or sham treatment in the Aura-sponsored clinical trial AU-011-301.\n* Be willing and able to consent to the AU-011-403 study.\n\nExclusion Criteria:\n\n* None",{"count":18,"type":19},"AU-011-403 is a multicenter long-term follow-up safety and efficacy study of subjects with early CM who previously participated in the AU-011-301 Phase 3 trial. There are no required interventions or use of AU-011 (bel-sar) in this long-term follow-up study",[25,26],[28,73],"Small Choroidal Melanoma","NOT_YET_RECRUITING","2026-01-07",{"date":77,"type":35},"2026-01-14",{"date":79,"type":19},"2026-02-01",{"date":81,"type":19},"2033-08-15",{"name":41,"class":42},""]